These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 18190252)

  • 1. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial.
    Martin JE; Pierson TC; Hubka S; Rucker S; Gordon IJ; Enama ME; Andrews CA; Xu Q; Davis BS; Nason M; Fay M; Koup RA; Roederer M; Bailer RT; Gomez PL; Mascola JR; Chang GJ; Nabel GJ; Graham BS
    J Infect Dis; 2007 Dec; 196(12):1732-40. PubMed ID: 18190252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.
    Ledgerwood JE; Pierson TC; Hubka SA; Desai N; Rucker S; Gordon IJ; Enama ME; Nelson S; Nason M; Gu W; Bundrant N; Koup RA; Bailer RT; Mascola JR; Nabel GJ; Graham BS;
    J Infect Dis; 2011 May; 203(10):1396-404. PubMed ID: 21398392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.
    Schneeweiss A; Chabierski S; Salomo M; Delaroque N; Al-Robaiy S; Grunwald T; Bürki K; Liebert UG; Ulbert S
    Vaccine; 2011 Aug; 29(37):6352-7. PubMed ID: 21596075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse.
    El Garch H; Minke JM; Rehder J; Richard S; Edlund Toulemonde C; Dinic S; Andreoni C; Audonnet JC; Nordgren R; Juillard V
    Vet Immunol Immunopathol; 2008 Jun; 123(3-4):230-9. PubMed ID: 18372050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults.
    Woods CW; Sanchez AM; Swamy GK; McClain MT; Harrington L; Freeman D; Poore EA; Slifka DK; Poer DeRaad DE; Amanna IJ; Slifka MK; Cai S; Shahamatdar V; Wierzbicki MR; Amegashie C; Walter EB
    Vaccine; 2019 Jul; 37(30):4222-4230. PubMed ID: 30661836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.
    De Filette M; Soehle S; Ulbert S; Richner J; Diamond MS; Sinigaglia A; Barzon L; Roels S; Lisziewicz J; Lorincz O; Sanders NN
    PLoS One; 2014; 9(2):e87837. PubMed ID: 24503579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.
    Chu JH; Chiang CC; Ng ML
    J Immunol; 2007 Mar; 178(5):2699-705. PubMed ID: 17312111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions.
    Chaintoutis SC; Diakakis N; Papanastassopoulou M; Banos G; Dovas CI
    Clin Vaccine Immunol; 2015 Sep; 22(9):1040-9. PubMed ID: 26178384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.
    Long MT; Gibbs EP; Mellencamp MW; Bowen RA; Seino KK; Zhang S; Beachboard SE; Humphrey PP
    Equine Vet J; 2007 Nov; 39(6):491-7. PubMed ID: 18065305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses.
    Liu SA; Haque M; Stanfield B; Andrews FM; Roy AA; Kousoulas KG
    Vet Microbiol; 2017 Jan; 198():51-58. PubMed ID: 28062007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.
    Muraki Y; Fujita T; Matsuura M; Fuke I; Manabe S; Ishikawa T; Okuno Y; Morita K
    Virol J; 2015 Apr; 12():54. PubMed ID: 25889682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines.
    Hughes HR; Crill WD; Davis BS; Chang GJ
    Virology; 2012 Mar; 424(2):129-37. PubMed ID: 22244913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newcastle disease virus-vectored West Nile fever vaccine is immunogenic in mammals and poultry.
    Wang J; Yang J; Ge J; Hua R; Liu R; Li X; Wang X; Shao Y; Sun E; Wu D; Qin C; Wen Z; Bu Z
    Virol J; 2016 Jun; 13():109. PubMed ID: 27342050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus.
    Shrestha B; Ng T; Chu HJ; Noll M; Diamond MS
    Vaccine; 2008 Apr; 26(16):2020-33. PubMed ID: 18339459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.
    Volz A; Lim S; Kaserer M; Lülf A; Marr L; Jany S; Deeg CA; Pijlman GP; Koraka P; Osterhaus AD; Martina BE; Sutter G
    Vaccine; 2016 Apr; 34(16):1915-26. PubMed ID: 26939903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.
    Goo L; Debbink K; Kose N; Sapparapu G; Doyle MP; Wessel AW; Richner JM; Burgomaster KE; Larman BC; Dowd KA; Diamond MS; Crowe JE; Pierson TC
    Nat Microbiol; 2019 Jan; 4(1):71-77. PubMed ID: 30455471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine.
    Samina I; Havenga M; Koudstaal W; Khinich Y; Koldijk M; Malkinson M; Simanov M; Perl S; Gijsbers L; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2007 Nov; 25(49):8338-45. PubMed ID: 17977629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. West Nile virus-specific immunoglobulin isotype responses in vaccinated and infected horses.
    Khatibzadeh SM; Gold CB; Keggan AE; Perkins GA; Glaser AL; Dubovi EJ; Wagner B
    Am J Vet Res; 2015 Jan; 76(1):92-100. PubMed ID: 25535666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-structural protein 1 (NS1) antibody-based assays to differentiate West Nile (WN) virus from Japanese encephalitis virus infections in horses: effects of WN virus NS1 antibodies induced by inactivated WN vaccine.
    Kitai Y; Kondo T; Konishi E
    J Virol Methods; 2011 Jan; 171(1):123-8. PubMed ID: 20974180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.